dc.contributor.author |
Lei, Beilei |
|
dc.contributor.author |
Mace, Brian |
|
dc.contributor.author |
Dawson, Hana N |
|
dc.contributor.author |
Warner, David S |
|
dc.contributor.author |
Laskowitz, Daniel T |
|
dc.contributor.author |
James, Michael L |
|
dc.coverage.spatial |
United States |
|
dc.date.accessioned |
2017-05-01T17:22:04Z |
|
dc.date.available |
2017-05-01T17:22:04Z |
|
dc.date.issued |
2014 |
|
dc.identifier |
https://www.ncbi.nlm.nih.gov/pubmed/25080336 |
|
dc.identifier |
PONE-D-14-14610 |
|
dc.identifier.uri |
https://hdl.handle.net/10161/14241 |
|
dc.description.abstract |
Female sex is associated with improved outcome in experimental brain injury models,
such as traumatic brain injury, ischemic stroke, and intracerebral hemorrhage. This
implies female gonadal steroids may be neuroprotective. A mechanism for this may involve
modulation of post-injury neuroinflammation. As the resident immunomodulatory cells
in central nervous system, microglia are activated during acute brain injury and produce
inflammatory mediators which contribute to secondary injury including proinflammatory
cytokines, and nitric oxide (NO) and prostaglandin E2 (PGE2), mediated by inducible
NO synthase (iNOS) and cyclooxygenase-2 (COX-2), respectively. We hypothesized that
female gonadal steroids reduce microglia mediated neuroinflammation. In this study,
the progesterone's effects on tumor necrosis factor alpha (TNF-α), iNOS, and COX-2
expression were investigated in lipopolysaccharide (LPS)-stimulated BV-2 microglia.
Further, investigation included nuclear factor kappa B (NF-κB) and mitogen activated
protein kinase (MAPK) pathways. LPS (30 ng/ml) upregulated TNF-α, iNOS, and COX-2
protein expression in BV-2 cells. Progesterone pretreatment attenuated LPS-stimulated
TNF-α, iNOS, and COX-2 expression in a dose-dependent fashion. Progesterone suppressed
LPS-induced NF-κB activation by decreasing inhibitory κBα and NF-κB p65 phosphorylation
and p65 nuclear translocation. Progesterone decreased LPS-mediated phosphorylation
of p38, c-Jun N-terminal kinase and extracellular regulated kinase MAPKs. These progesterone
effects were inhibited by its antagonist mifepristone. In conclusion, progesterone
exhibits pleiotropic anti-inflammatory effects in LPS-stimulated BV-2 microglia by
down-regulating proinflammatory mediators corresponding to suppression of NF-κB and
MAPK activation. This suggests progesterone may be used as a potential neurotherapeutic
to treat inflammatory components of acute brain injury.
|
|
dc.language |
eng |
|
dc.publisher |
Public Library of Science (PLoS) |
|
dc.relation.ispartof |
PLoS One |
|
dc.relation.isversionof |
10.1371/journal.pone.0103969 |
|
dc.subject |
Animals |
|
dc.subject |
Anti-Inflammatory Agents |
|
dc.subject |
Cell Line |
|
dc.subject |
Cyclooxygenase 2 |
|
dc.subject |
Drug Evaluation, Preclinical |
|
dc.subject |
Extracellular Signal-Regulated MAP Kinases |
|
dc.subject |
Female |
|
dc.subject |
Lipopolysaccharides |
|
dc.subject |
Mice |
|
dc.subject |
Microglia |
|
dc.subject |
NF-kappa B |
|
dc.subject |
Nitric Oxide Synthase Type II |
|
dc.subject |
Phosphorylation |
|
dc.subject |
Progesterone |
|
dc.subject |
Protein Processing, Post-Translational |
|
dc.subject |
Protein Transport |
|
dc.subject |
Receptors, Progesterone |
|
dc.subject |
Tumor Necrosis Factor-alpha |
|
dc.title |
Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated BV-2 microglia. |
|
dc.type |
Journal article |
|
duke.contributor.id |
Dawson, Hana N|0145799 |
|
duke.contributor.id |
Warner, David S|0116342 |
|
duke.contributor.id |
Laskowitz, Daniel T|0056656 |
|
duke.contributor.id |
James, Michael L|0225034 |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/25080336 |
|
pubs.begin-page |
e103969 |
|
pubs.issue |
7 |
|
pubs.organisational-group |
Anesthesiology |
|
pubs.organisational-group |
Anesthesiology, Neuroanesthesia |
|
pubs.organisational-group |
Basic Science Departments |
|
pubs.organisational-group |
Clinical Science Departments |
|
pubs.organisational-group |
Duke |
|
pubs.organisational-group |
Duke Clinical Research Institute |
|
pubs.organisational-group |
Duke Institute for Brain Sciences |
|
pubs.organisational-group |
Institutes and Centers |
|
pubs.organisational-group |
Institutes and Provost's Academic Units |
|
pubs.organisational-group |
Neurobiology |
|
pubs.organisational-group |
Neurology |
|
pubs.organisational-group |
Neurology, Neurocritical Care |
|
pubs.organisational-group |
Neurosurgery |
|
pubs.organisational-group |
School of Medicine |
|
pubs.organisational-group |
Surgery |
|
pubs.organisational-group |
University Institutes and Centers |
|
pubs.publication-status |
Published online |
|
pubs.volume |
9 |
|
dc.identifier.eissn |
1932-6203 |
|
duke.contributor.orcid |
Laskowitz, Daniel T|0000-0003-3430-8815 |
|
duke.contributor.orcid |
James, Michael L|0000-0002-8715-5210 |
|